KILITCH.BO Kilitch (BSE) down 51.52% pre-market 25 Mar 2026: key INR 140 support

KILITCH.BO stock opened the pre-market session sharply lower on 25 Mar 2026 after price fell to INR 152.80, down -162.40 or -51.52% from the previous close of INR 315.20. The move shows heavy interest with volume 4,166 versus an average 999, and the intraday range is INR 140.25–160.00. Traders should note the year low at INR 140.25 and the 50-day average at INR 328.61, which frames the scale of the sell-off and the immediate technical support levels.

KILITCH.BO stock: pre-market price action and liquidity

The stock trades on BSE and shows a pre-market price of INR 152.80. The one-day change is -51.52% with a net move of -INR 162.40 from INR 315.20. Reported volume is 4,166, giving a relative volume of 4.17 versus an average of 999, signalling concentrated selling interest in early trade.

KILITCH.BO stock: valuation and balance-sheet metrics

Kilitch Drugs (India) Limited reports EPS INR 15.69 and a quoted PE of 9.74 on current price levels. Price to book is 2.01, and market capitalization is about INR 5.34B. The company shows a healthy current ratio of 2.53 and debt to equity of 0.31, indicating manageable leverage despite the sharp price decline.

KILITCH.BO stock: technicals show deep oversold readings

Momentum indicators are extreme; RSI at 14.91 and MACD histogram negative at -15.86. The 50-day moving average sits at INR 328.61, the 200-day at INR 374.60, and Bollinger middle band at INR 303.59, placing the current price well below trend. The immediate support is the year low INR 140.25 and resistance near the intraday high INR 160.00.

KILITCH.BO stock: Meyka AI rates and price forecast

Meyka AI rates KILITCH.BO with a score of 76.02 out of 100 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly INR 370.01, quarterly INR 451.88, and yearly INR 457.29. Versus the current INR 152.80, the yearly projection implies an upside of 199.33%. Forecasts are model-based projections and not guarantees.

KILITCH.BO stock: sector context, catalysts and news links

Kilitch sits in the Healthcare sector where average P/E is about 36.56, so the stock’s P/E of 9.74 is materially lower than peers. Key near-term catalysts include the earnings announcement on 18 May 2026 and any company updates on exports or product approvals. Recent coverage is available on MarketWatch and the company site; see MarketWatch report and Kilitch website.

KILITCH.BO stock: short-term trading idea and price targets

For short-term traders, a conservative near-term recovery target is INR 200.00 with a stop-loss under INR 140.25 to limit downside. A medium-term recovery scenario targets the 50-day mean at INR 328.61. These levels are scenario-based price targets and not buy or sell recommendations.

Final Thoughts

KILITCH.BO stock is a clear pre-market top loser on 25 Mar 2026 after a -51.52% move to INR 152.80 on heavy relative volume. The drop pushed technical indicators to deeply oversold readings, with RSI 14.91 and price far below both the 50-day (INR 328.61) and 200-day (INR 374.60) averages. Fundamentals show mixed signals: an EPS of INR 15.69, a quoted PE of 9.74, solid current ratio 2.53, and manageable debt-to-equity 0.31. Meyka AI rates KILITCH.BO 76.02/100 (B+, BUY) and projects a yearly price of INR 457.29, implying 199.33% upside from today’s level; this is a model projection, not a guarantee. Short-term players can watch INR 140.25 support and INR 160.00–200.00 resistance zone. Investors looking for a turnaround should wait for clearer liquidity and operational signals. Meyka AI’s platform provides this as AI-powered market analysis, but any position must account for the stock’s very high intraday volatility and sector comparatives on BSE in INR.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.